These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20814894)

  • 21. Rifaximin for the treatment of hepatic encephalopathy.
    Lawrence KR; Klee JA
    Pharmacotherapy; 2008 Aug; 28(8):1019-32. PubMed ID: 18657018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of rifaximin in management of hepatic encephalopathy.
    Wahib AA; El-Deen Salem MN; Ahmed MA; El-Dessouky YM; El-Tiby DM; El-Mola K; El-Sayed AM
    J Egypt Soc Parasitol; 2014 Dec; 44(3):677-85. PubMed ID: 25643509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
    Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rifaximin in the treatment of chronic hepatic encephalopathy.
    Puxeddu A; Quartini M; Massimetti A; Ferrieri A
    Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes.
    Courson A; Jones GM; Twilla JD
    J Pharm Pract; 2016 Jun; 29(3):212-7. PubMed ID: 25586470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver: the gut is a key target of therapy in hepatic encephalopathy.
    Sawhney R; Jalan R
    Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):7-8. PubMed ID: 25348849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomics of hepatic encephalopathy.
    Neff G
    Pharmacotherapy; 2010 May; 30(5 Pt 2):28S-32S. PubMed ID: 20412038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifaximin and nonabsorbable disaccharides for hepatic encephalopathy.
    Guslandi M; Cella A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):376. PubMed ID: 20134260
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hepatic encephalopathy. Rifaximin opens new perspectives].
    MMW Fortschr Med; 2014 Jul; 156(13):78-9. PubMed ID: 25318235
    [No Abstract]   [Full Text] [Related]  

  • 31. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.
    Bucci L; Palmieri GC
    Curr Med Res Opin; 1993; 13(2):109-18. PubMed ID: 8325041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Utzt MJ
    MMW Fortschr Med; 2015 Jun; 157 Suppl 2():54. PubMed ID: 26048124
    [No Abstract]   [Full Text] [Related]  

  • 34. Rifaximin: a nonabsorbed oral antibiotic.
    Baker DE
    Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to Congly and Leise.
    Praveen S; Chander SB
    Am J Gastroenterol; 2014 Apr; 109(4):598-9. PubMed ID: 24698865
    [No Abstract]   [Full Text] [Related]  

  • 36. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?
    Henderson PK; Herrera JL
    Clin Liver Dis; 2015 Aug; 19(3):487-95. PubMed ID: 26195203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L
    Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifaximin for the treatment of hepatic encephalopathy.
    Mullen K; Prakash R
    Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver.
    Ali B; Zaidi YA; Alam A; Anjum HS
    J Coll Physicians Surg Pak; 2014 Apr; 24(4):269-73. PubMed ID: 24709242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving treatments for hepatic encephalopathy.
    Gastroenterol Nurs; 2012; 35(4):291-2. PubMed ID: 22847290
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.